Dapagliflozin

Indication

Triple therapy for treating type 2 diabetes (NICE TA418)

NICE TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Green

Brand:

Forxiga®

Nice TA:

418

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:

Endocrine system

Background

Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.
The LSCMMG recommends dapagliflozin as a 1^st line ““gliflozin””.

Recommendation

LSCMMG Recommendation:

Green

Reason for decision:

Suitable for initiation in primary care

Supporting documents:

Algorithm For Antihyperglycaemic Therapy In Adults With Type II (Version 1.5)

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Green	Green	Green	Green	Green	Green	Green	Green

What do the colours mean?

Last Updated: 01 - Dec - 2016